An ambispective cohort study to determine efficacy and safety of pembrolizumab combination in real world setting in patients with early triple negative breast cancer
Latest Information Update: 09 Feb 2023
At a glance
- Drugs Pembrolizumab (Primary) ; Carboplatin; Paclitaxel
- Indications Early breast cancer; HER2 negative breast cancer
- Focus Adverse reactions; Pharmacokinetics
Most Recent Events
- 09 Feb 2023 New trial record
- 10 Dec 2022 Results presented at the 45th Annual San Antonio Breast Cancer Symposium